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Preliminary Studies into DNA Binding Capabilities of Ruthenium Nitro 
Nitrosyl as Anti-Tumor Pro-drugs 
Abstract 
The complex [Ru(bpy)z(NO)(N02)](PF6)2 was investigated as a potential anti­ 
tumor drug option. The nitrosyl group was displaced by reaction with azide ion in 
acetone to yield the solvento complex in situ. The products isolated from addition of a 
solution or slurry of guanine, adenine, cytosine or thiamine to the resulting 
[Ru(bpy)(N02)(acetone)t were investigated by electronic absorption spectroscopy, infra­ 
red spectroscopy, 1H NMR spectroscopy and cyclic voltammetry. The results of the 
studies showed that guanine, adenine and thiamine form adducts with 
Ru(bpy)z(N02)(acetone)t. However, each base forms a unique complex as shown by 
electronic spectroscopy. Guanine is the strongest field ligand, indicating likely 
coordination to N-7. The spectrum of the adenine adduct was consistent with the ligand 
exerting a slightly weaker field than guanine. This may be indicative of binding to the 
primary amine site. The thiamine adduct was weaker field yet, but still clearly different 
from the solvento complex. Thiamine presents several potential binding sites, thus, many 
may be involved. Cytosine showed no evidence of binding. 
In the case of adenine and thiamine, the hydrochloride salts were used, and gave 
the unexpected, but welcome, result of converting some of the nitro complexes to the 
corresponding nitrosyl, [Ru(bpy)2(NO)(base)]\ according to well-known chemistry. The 
pK. for the nitro to nitrosyl conversion is typically around 6.4, which indicates that under 
physiological conditions, a significant fraction of the complex will be in the nitrosyl 
form. As it is known that biologically active reducing agents such as NAD+ can reduce 
2 
coordinated nitrosyls to the nitroxyl radical (and even further, to NH3, given sufficient 
reducing equivalents), the chemistry described above presents a viable method for 
introducing the nitroxyl radical into DNA. Since tumors tend to be hypoxic, formation of 
site specifically localized nitroxyl radical can have profound implications. 
As further proof of concept, Z8A 8 mer (CG)4 DNA strand was reacted with 
excess ruthenium nitro nitrosyl compound, and separated via size exclusion 
chromatography. Two distinct bands were observed when the sample was running 
through the burette, demonstrating that the ruthenium complex did in fact bond to the 
(CG)4 DNA sequence. 
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Introduction Section 
The ongoing battle to find anti-tumor drugs that do not have significant toxic side 
effects continues to plague society. With the number of deaths due to cancer on the rise 
each year, this crucial issue has become the focal point ofresearch around the country 
and world. The National Cancer Institute estimates that approximately 1 1 . 1  million 
Americans with a history of cancer were alive in January 2005. Some of these 
individuals were cancer-free, while others still had evidence of cancer and may have been 
undergoing treatment.' Several avenues of cancer treatment research have been 
followed, including heavy metal compounds as transcription inhibitors. 
Cisplatin, (cis-Pt(NH3)2Ch), is a current anti-tumor drug treatment. It is square 
planar in geometry and binds to DNA by forming intrastrand cross-links primarily 
between adjacent guanine bases (-GG- ). These cross-links result in significant bends in 
and untwisting of the DNA strand, leaving it inactive to transcription/ Cisplatin binds to 
DNA by first undergoing through sequential thermal ligand exchange ( chlorides to 
hydroxides, cis-Pt(NH3)2Ch --. cis-Pt(NH3)2(0Hh) and then displacement of the 
hydroxides by N-7 of guanine, particularly the GpG DNA sequences (adjacent 
guanines). 2 However, cisplatin tends to prefer bonding with proteins instead of DNA. 
This is because platinum is a very soft Lewis acid, and prefers binding to softer sulfur 
donor sites, often found in proteins. This protein binding is thought to be one contributor 
to the highly toxic side effects associated with cisplatin chemotherapy. 
This has led to investigation of ruthenium complexes as potential drug therapy 
options, and indeed, complexes such as Ru(tpy)C'3, (tpy = 2,2':6' ,2" -terpyridine) and 
[Ru(NH3)sCit have found chemotherapeutic use. Ruthenium is thought to bond to DNA 
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in a similar fashion to cisplatin, linking adjacent guanines, thereby disrupting cellular 
transcription. Ruthenium is a group VIII metal, and is found predominantly in the Ru(II) 
and Ru(III) oxidation states.' It is a six-coordinate metal that displays an octahedral 
geometry as opposed to the square planar geometry of cisplatin. Further, ruthenium is 
expected to have less of an affmity to sulfur as it is a harder metal ion, ideally suited to 
nitrogen specific binding. As such, ruthenium complexes will be less likely to prefer 
binding to sulfur in proteins over the nitrogen in DNA. Ruthenium complexes have an 
'activation by reduction' mechanism and have been shown to preferentially localize in 
tumor tissues. 3 This is possibly because the pH is lower in tumor cells than in regular 
tissue cells, which causes their electrochemical potential to be lower. 3 
Ru(II) is kinetically more labile than Ru(III), but Ru(III) is activated by reduction 
in vivo to more rapidly coordinate to biomolecules. Because gluthione in the cell and 
ascorbic acid in the blood are reducing agents they are thought to contribute to reducing 
Ru(III) complexes in the body.3 This is what has given rise to the belief that Ru(III) 
complexes could serve as pro-drugs. Ruthenium nitrosyl complexes have been suggested 
as possible antitumor agents that also releases NO (nitric oxide) within the tumor cells.4 
Ru(II) and Ru(III) selectively bind to imine sites in biomolecules as the lone pair is 
available for metal ion coordination due to the high pKb.3 More specifically, they are 
thought to coordinate nitrogens either on the imidazole aromatic ring on histidine proteins 
or purine nucleotides, which suggests that they prefer binding to purines like guanine 
similar to cisplatin. 3 This coordination targets in vivo proteins and nucleic acids. Binding 
to transferrin is thought to facilitate ruthenium transport into cells and could be a possible 
avenue of drug administration. The anti-tumor properties of ruthenium complexes are 
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thought to be due to their interactions with DNA nucleobases. Like cisplatin, the 
preferred binding site of known reactive ruthenium complexes is guanine (N7) with some 
binding to adenine and cytosine.' Ruthenium bipyridine complexes, [Ru(bpy)3]2+ in 
particular, shows a very weak association with DNA, mainly due to its electrostatic 
interactions with the DNA phosphates.4 
The photoreactivity of ruthenium polypyridine complexes and noncoordinative 
DNA binding have been a subject of interest and research in the past few years.4 
Ruthenium diamine, cis-[Ru(bpy)2(NH3)2]2+, has recently become a subject of interest in 
anti-tumor studies. It is thought that ruthenium diamine could be used as a photodynarnic 
therapy drug (PDT drug). Ruthenium diarnine is photoreactive, undergoing arnmine loss 
upon irradiation. The basic concept of PDT is the drug is injected into the body, and then 
light is shined on the specific tumor area. This, in theory, would cause the complex to 
react and bond to adjacent guanines in DNA and disable the strand. The distance 
between the bound complex and the DNA helix plays a key role in DNA photocleavage.4 
However, because the ruthenium diamine complexes are photoreactive when closely 
associated to any biopolymer, recent studies have shown that this is rather problematic as 
the complexes setm..to react differently depending on what other biological structures 
surround it, and it more readily undergoes water substitution than many have realized. 
The reaction rate has also been difficult to determine effectively, which delays the 
progress of using these complexes as anti-tumor drugs. 
This has turned attention to other ruthenium complexes as possible anti-tumor 
drugs. Of particularly interest to this work is the investigation of polypyridyl ruthenium 
nitrosyl and nitro complexes. One question of interest is the form of these complexes 
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(i.e., nitro nitrosyl) in the body.4 This seems to depend on the ruthenium coordination 
sphere, and the nature of the co-ligands.4 The current approach speculated upon in the 
literature is based on a theoretical mechanism involving the reaction of the ruthenium 
nitrosyl compound in the presence of a DNA base. The nitrosyl group is expected to be 
lost during the reaction, and replaced by a DNA nucleobase, most likely guanine. If this 
bonding is accomplished on a full DNA strand, it has been stated that the ruthenium 
complex would theoretically link adjacent guanines, like cisplatin, and untwist the DNA 
strand. How the second bond is formed has not been stated. Cytosine and adenine 
nucleobases are possible binding sites as well, yet there is little evidence to suggest 
otherwise. The reason this particular mechanism is thought to be ideal is because the 
reaction is generally considered to be a photodissociative mechanism. It is interesting 
that this approach is based on loss of the very strong field ligand NO, and only 
speculation of the value of in situ produced nitroxide radical is considered. 
This ruthenium complex is believed to react in cancer cells due to the more 
hypoxic and acidic environments found in cancer cells as relative to healthy cells. 
Normal cells are expected to yield an unreactive environment, maintaining the NOx group 
as nitro due to the higher basicity. Further, ruthenium is a borderline metal according to 
Hard-Soft Acid-Base Theory, it should have a lower affinity for sulfur in proteins and 
preferentially bind to the nitrogen in DNA nucleobases when introduced in the body. 
The work done at the Chemistry Department University of Ioannina by Garoufis and 
associates determined that the ruthenium polypyridine nitrosyl complexes they studied 
transformed are to their nitro derivatives at neutral pH in solution.4 This leads to more 
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questions concerning form of the complex in biological cell systems, more specifically, 
tumor cells as opposed to normal cells. 
Interestingly, Garoufis investigated Ru(tpy)(AA)(NO) complexes, where AA is a 
sterically strained ligand (2,2'-dipyridyl ketone or 2,2'-dipyridyl amine), and his 
chemistry is based on the loss of the nitrosyl group prior to binding.4 These ligands are 
not electron withdrawing, and favor the nitro form of the NOx ligand in the cell 
environment. An alternative complex, [Ru(bpy)2(N02)(0H2)]\ has a pK,. for the nitro to 
nitrosyl conversion of 6.5. 5 In buffer over twelve hours, equilibrium will be reached 
between the nitro and nitrosyl species. Stronger field ligands appear to facilitate this 
process by raising the pK. for the conversion. In a separate study by Meyer ,6 it has been 
shown that coordinated nitrosyl can be reduced by NADH, which is a coenzyme found in 
biological cells. The NADH donates an electron to the nitrosyl and produces nitroxide. 
Nitroxide is rapidly consumed in cells, and acts as a signaling agent for several processes, 
such as vasodialation. However, it is also a free radical which will cause an attack on the 
DNA structure, triggering free radical damage. Since the nitrosyl remains coordinated to 
the ruthenium ion, this can be an electrocatalytic process. It would seem that instead of 
losing the nitrosyl group upon binding to DNA, with the release of NO+ (which cannot be 
reduced without being coordinated to a metal") a better strategy would be to try to bind 
the [Ru(bpy2)(N02)] fragment to DNA. In the acidic and hypoxic environment or cancer 
cells, the N02- would be converted to NO+ and reduced to NO and beyond. 
Therefore, in this study, in order to determine the potential future of ruthenium 
nitro nitrosyl as an anti-tumor drug, different DNA nucleobases and thiamine were 
reacted with the nitro nitrosyl complex, activated by reaction with azide ion, to determine 
if bonding can occur at all. Thiamine is a water soluble vitamin of the B complex and 
has several potential binding sites. This compound was also reacted with the ruthenium 
to determine how readily the ruthenium compound will bind to any available nitrogen or 
sulfur. 
The bases used to form nucleic acids fall into two classes - pyrimidines and 
purines: 
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cytosine ( C) thymine (T) 
Pyrimidines 
uracil (U) 
adenine (A) guanine (G) 
The hydrogens shown in red mark the location where the base binds to the sugar (ribose 
in RNA; deoxyribose in DNA); the green nitrogens show the known sites where metals 
bind.14 Given the Lewis basicity of the N-7 position in adenine and guanine, it is 
reasonable to expect that they would bind to complexes such as [Ru(bpy)2(N02)(S)t at 
this site. Previous work shows that ruthenium ammines and polypyridyl will bind to 
DNA strands and are effective as anti-tumor agents.15 We also examined the vitamin 
chloride salt of thiamine, given the structural similarity to the purines: 
NH2 
+ 
N� 
s 
10 
Thiamine 
OH 
Note that when involved in polymeric double stranded DNA, thymine and cytosine do 
not have free imines available for binding to metals, while adenine and guanine do. 
Thiamine is particularly intriguing since it affords several potential binding sites. 
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Experimental Section 
Materials: The solvents methanol (Mallinckrodt), acetone (Mallinckrodt) and 
acetonitrile (Phannco) were ACS reagent grade and used as received. The reagents HPF6 
(96%), Z8A 8 mer DNA strand which is (CG)4, guanine, acetone-d, 99.9 atom %0, 
deuterium oxide 99 .9 atom %0, tetrabutylammonium chloride sodium nitrite and sodium 
azide were acquired from Sigma-Aldrich and used as received. The acetone-d, used for 
NMR measurements contained 0.03 % v/v tetramethyl silane as an internal standard. 
Adenine hydrochloride hemihydrate 98%, thiamine hydrochloride 99%, cytosine 98%, 
and 2,2' -bipyridine were purchased from Alfa-Aesar and used as received. Anhydrous 
ether was purchased in I L cans from J.T. Balcer. The starting material ofRu(bpy)2Ch 
was provided by Dr. Murphy at Seton Hall University. All aqueous solutions were 
prepared from distilled and deionized water (18 Mil) obtained from the Seton Hall 
University Chemistry Department Millipore purifier. Filter paper was Whatman #2. 
Zero grade nitrogen and argon were obtained from AGL. 
Electronic spectra were measured on a Hewlett Packard 8452A diode array 
spectrophotometer rebuilt by OLIS in 2007. Infra-red spectra were obtained on a Nicolet 
4700 FT-IR from Thermo Electron Corporation. Cyclic and Osteryoung square wave 
voltammograms measured on a BAS CV-SOW Voltammetric Analyzer. The voltages 
were referenced against an Ag/ AgCI (saturated, aqueous NaCl) electrode constructed in 
our laboratory. The auxiliary electrode was a platinum wire (Alfa Aesar) and the 
working electrode was either a Pt disk (for nonaqueous measurements) or a glassy carbon 
disk electron (for aqueous measurements) purchased from Bioanalytical Systems. 
Working electrodes were polished with aqueous slurries of 2µ alumina on microcloth 
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mounted on a Plexiglas sheet (all obtained from BAS). 1H and I3c NMR spectra were 
run on a Varian Inova 500 MHz NMR using VNMR-J 2.2d software on a Dell quad core 
workstation with Red Hat Linux Enterprise software ( all obtained from Varian). The fid 
files were copied onto commercial flash drives and processed with ACDLABS ID NMR 
software. 
Syntheses: The starting material Ru(bpy)i(N02)2 was prepared by literature 
methods.15 The Ru(bpy)iClz complex (1.0 g) was slurried in 60 mL of distilled water 
H20 in a I 00 mL a round bottom flask, and refluxed for 20 minutes. The dark red 
solution was filtered using a glass frit to remove any undissolved materials. The filtrate 
was returned to the rinsed round bottom flask and 3.0 g ofNaN02 was added. The 
solution was refluxed for one hour. The reaction mixture was cooled. The brick red solid 
was isolated by filtration via a glass frit, washed with water and then methanol to yield 
Ru(bpy)2(N02)2 (1). 
[Ru(bpy)i(N02)(NO)J(PF 6)2: This complex was prepared as described in 
reference 7. The complex (1) was suspended in 20 mL of methanol in a I 00 mL 
Erlenmeyer flask and stirred with glass beads (ca 3 mm diameter). Approximately 1.0 
mL ofHPF6 (95%) was added drop-wise while stirring over a 5 minute period (caution: 
HPF6 is highly caustic and will dissolve the Pasteur pipet used/or transfer in 
approximately an hour. Transfer rapidly, use heavy gloves, lab coat and/ace shield). 
The red solution clarified and a peach colored precipitate formed. The precipitate was 
isolated by via filtration with a glass frit and washed with methanol. This yielded 
[Ru(bpy)2(N02)(NO)](PF6)J (2). Cyclic voltammetry yielded the characteristic 
voltammogram of the complex and verified the absence of impurities. 
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General synthetic procedure for preparation of the ruthenium-base adducts: 
Under argon gas, 0.1023 g of(2) was dissolved in 50 mL of deaereated acetone in a 
round bottom flask and 7.0 mL of a 1.7 x 10-5 M solution ofNalv, was titrated into the 
flask over 10 minutes using a dropping funnel. Upon completion, the dropping funnel 
was then rinsed with methanol to ensure quantitative transfer of the sodium azide. An 
aqueous slurry of a molar excess of either, adenine hydrochloride hemihydrate, thiamine 
hydrochloride, guanine, or cytosine was titrated into the solution. The solution was 
refluxed for one hour, filtered using a Buchner funnel and filter paper to remove unbound 
base, stored overnight in a refrigerator to precipitate, and then concentrated using a rotary 
evaporator to complete precipitation. The precipitate was isolated on a glass frit to 
produce [Ru(bpy)z(N02)L] (PF6) (3), which was the desired product (the L represents the 
deoxyribonucleic acid nucleobase present). The product was dried in a vacuum 
dessicator over Drierite. The solid was redissolved in acetone or acetonitrile, and added 
dropwise to stirring anhydrous ether to reprecipitate. The solution was filtered to obtain 
powder dry product, which was stored in a desiccator. As the study was to determine if 
deoxyribonucleic acid nucleobase and ruthenium bonding could occur, percent yields 
were not obtained. 
Reaction of2 with oligomeric DNA: To determine binding preference, 0.004g of 
(2) was dissolved in a few milliliters of deaerated acetone, and then added to 25 mL of 
deaerated water in a 50 mL round bottom flask. Sodium azide (0.2 mL of 1. 7 x 10-5 M 
solution) was added dropwise to the flask. The oligonucleotide Z8A was dissolved in a 
small amount of water and added dropwise. The solution was refluxed for one hour. The 
solution was cooled and a saturated solution ofKPF6 in water was added dropwise. The 
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reaction mixture was refrigerated overnight. The solution was concentrated using a 
rotary evaporator until a precipitate was observed. The precipitate was isolated, dried 
and dissolved in acetone. A saturated acetone solution of tetrabutylammonium chloride 
was added to exchange the anion from PF6- to er. The solution was filtered and 
concentrated to one mL. Solid blue dextran was added as a high molecular weight 
marker to the solution. A gravity feed chromatography column (ca 20 cm by 2.5 cm) was 
slurry packed with Sephadex LH-20 size exclusion resin swelled overnight water. The 
isolate was charged on the column and eluted with water. A blue band (blue dextran) 
eluted with the void volume and two red bands were eluted afterwards, confirming the 
formation of the ruthenium-oligonucleotide adduct. 
Spectroscopic determinations: For electronic spectroscopy, an aqueous solution 
of each of the complexes was prepared in the 1.23 x 10-4 M to 2.0 x 10-4 range. Four 
dilutions were made volumetrically and the spectra were recorded from 210-600 nm. For 
infrared spectroscopy, the compounds were dissolved in acetonitrile and IR spectra were 
run from 400-4000 cm·1 in a I mm liquid cell with NaCl windows. 
Electrochemical measurements: Cyclic voltammetry was run on each sample to 
confirm the presence of the nitro group. Samples were dissolved in a 0.1 M solution of 
tetrabutyl ammonium hexafluorophosphate. The initial voltage was set to 0.0 volts, two 
second hold time, and the high voltage E was set to + 1.400 V. Scans were initially in the 
positive direction and run at I 00 m V s". 
NMR spectrometry: NMR spectra using the standard programs from Varian were 
obtained on (2) and 2,2'-bipyridine in deuteroacetone. The [Ru(bpy)2(N02)(X)]2+ 
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complexes were dissolved in deuterium oxide after several hours in a vacuum desecrator 
after a persistent water peak continued to show up in NMR scans using deuteroacetone. 
Only 
1 H NMR scans were run on the ruthenium nitro DNA nucleobase complexes due to 
issues dissolving enough compound in a solution to obtain a satisfactory concentration in 
order to obtain an NMR signal. 
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Results Section 
Syntheses, yields and analyses - Addition of azide ion to the solutions of 
[Ru(bpy)2(N02)(N0)]2+ promptly generated the characteristic dark red of the acetone 
complex. Further reaction with the bases generated no clearly perceptible changes in 
color in the reaction mixture, but electronic spectroscopy (vide infra) was able to 
discriminate between the reaction products. Generally, the PF6- salts were difficult to 
dry, even with overnight storage in a vacuum dessicator with Drierite (future studies 
should investigate the use of P20, and possibly vacuum ovens). When observing the three 
DNA base-ruthenium compounds and the thiamine-ruthenium compound, it is evident 
that some of the Lewis bases replaced solvent, as they are all different colors. When 
dissolved in deuteroacetone, the cytosine and adenine-ruthenium complexes were the 
same color, a reddish orange, as was the thiamine-ruthenium complex. However, the 
guanine-ruthenium compound was a different color, more of a dark red. The thiarnine­ 
ruthenium and adenine- ruthenium complexes had a very small percent yield compared to 
the other complexes as well. All complexes contained a substantial amount of water by 
NMR, making determination of% yields for the reactions and microanalyses of products 
oflittle value in characterizing the complexes. Generally, microanalyses of polypyridyl 
complexes containing nitro and nitrosyl ligands are known to be problematic,5•7 as has 
been observed for cyano complexes.j" 
Electronic spectroscopy - The electronic spectra of the four complexes were 
obtained in water at four different concentrations, and the results summarized in Table I 
and Charts 1-9. Absorption bands were compared in aqueous solution for 
[Ru(bpy)2(N02)L](PF6) complexes, where L-NO+, guanine, adenine, cytosine, thiamine 
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and acetone (note: acetone is a poorly binding ligand, it is displaced by any Lewis base 
solvent, so the acetone complex in aqueous solution is really the aqua complex).8 The 
starting material is weakly absorbing in the 380-600 nm region, as expected for 
ruthenium polypyridyl complexes with nitrosyl ligands. All other complexes displayed 
the characteristic Run-> it'(bpy) charge transfer bands centered around 440 nm with 
extinction coefficients of approximately 1 x 103 to 4 x lif. 
Plots of absorbance vs concentration were analyzed by Beer's Law, (A= sbc 
where A =  absorbance, E = extinction coefficient in M-1 cm"; b = pathlength; c = 
concentration in M), yielding the data in Table 1. The Beer's law plots in Charts 1-5 are 
linear with correlation coefficients of> 0.99, consistent with ideal solution behavior in 
this solvent and concentration range. Additional, intense intraligand 1t(bpy)->1t'(bpy) 
bands are observed in the higher energy regions and were not investigated further. 
Table I 
Analysis of the UV-Vis adsorption of the complexes at four different dilutions 
in water. 
Compound MDax e (M
1 cm") 
[Ru(bpy)i(N02)(NO)](PF•h 380 5.06 x 10' 
[Ru(bpy )i(N02)Guanine ](PF 6)2 418 I  468 4.16 x 10' I 3.70 x IO' 
[Ru(bpy)i(N02)Cytosine](PF6h 432 4.39 x 10' 
[Ru(bpy)i(N02)Adenine](PF6)2 460 3.08 x 10' 
[Ru(bpy)i(N02)Thiamine](PF6)2 452 1.37 x 10
3 
[Ru(bpy)i(N02XCH,)2CO](PF.)2 432 2.32 x 10' 
Because of the qualitative but small differences between the spectra for the 
solvento and cytosine species, these spectra were isolated in Chart 8, and the difference 
spectra calculated. Chart 9 indicates a small contribution form of ruthenium complex 
with a very weak field ligand, possibly the nitro hydroxo. 
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Chart I 
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Chart 3 
Beefs Law Plot of [Ru(bpy),(N02)Adenlne](PF1)2 
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Chart 5 
Bee(s Law Plot of [Ru(bpy)2(N02)Thiomlno](PF1)2 
0.25-,------------------------------, 
0.2 +----------------------------------l 
y = 0.0463x + O.Q09.i. 
R
2 
= 0.9939 
• 486nm 
-Linear (486 nm) 
0.05 +---------------------------------< 
O+-------�-------.------�-----------l 
2.14E-05 "4.28E-05 
Concentration (M) 
6.41E-05 8.SSE-05 
Chart 1-5: Beer's law plots of [Ru(bpy)i(N02)(L)](PF6)2 where L= nitrosyl, 
guanine, cytosine, adenine, thiamine, or solvent, acquired from four dilutions made 
in water. 
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Chart 6 
Absorption Band Shifts of Varying Ruthenium Nitro Compounds 
[Ru(bpy)2(NO,l(L)](PF 1)2 
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Chart 7 
[Ru(bpy),(NO,)(L)J(PF,), 
o-k,�����������������,.,.;;;;;;;;;;; 
# � � # # # � # # � � � # # # � # $ � # # # � # # # # # #  
Wav....,gth (nm) 
)6000-Wl.-1----------------------------i 
k -=--�-"'°"'-�- 
� - -�� 
8 L•Guanl'le 
� _.,,;::::::::::,.'c- -L=Cytolline 
8 4000 f---'�-\-\----->.,.--- , -L• -.no 
I WOO f---'----\-�--�.,,-_ _,tt --1 -L=Thiamr,e 
Chart 6 and 7: UV absorbance of [Ru(bpy)i(N02)(L)](PF6)2 where L= nitrosyl, 
guanine, cytosine, adenine, thiamin, or solvent, dissolved in water. 
Chart 8 
[Ru(bpy),(N02)(L)](PF ,), 
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Chart 8: UV absorbance of[Ru(bpy)z(N02XL)](PF6)2 where L= cytosine or 
solvent, dissolved in water. 
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Chart 9 
Difference Between Ru-Cytosine and Ru-Acetone Extinction Coefficierrts 
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Chart 9: Plot of the absorbance difference between [Ru(bpy)i(N02)(L)](PF•h 
where L= cytosine or solvent, dissolved in water. 
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Electrochemistry - Cyclic voltammetry scans from 0.0 V to 1.40 volts in 
acetonitrile/0.lM TBAH displayed an unsymmetrical oxidative wave with a broad return 
wave, characteristic of polypyridyl ruthenium nitro complexes. 7•9•10 Figures I a-d display 
the voltammetric data. This characteristic asymmetry verifies the presence of the nitro 
after the azido displacement reaction, as [Ru(bpy)2L2] complexes usually have well­ 
defined Ru11 � Rum waves. 
Nitrosyl complexes have a distinct, reversible wave around 300 m V due to 
reduction of the nitrosyl ligand. The absence of this reversible wave confirms the 
complete reaction of the nitrosyl ligand and its replacement by another Lewis base. 
There appears to be only one unsymmetrical peak in the+ 1.0-+0.8 volts for the guanine 
complex. The product of the cytosine shows a complex series of oxidations typical of 
multiple complexes. However, for the thiamine and adenine complexes the nitro 
unsymmetrical wave is accompanied by a reversible nitrosyl wave between +0.3- 0.0 
volts. The complexes were re-synthesized using excess sodium azide was used to ensure 
that all nitrosyl was cleaved. The nitrosyl peak was still found in the cyclic voltammetry 
scans, suggesting that the hydrochloride salts of adenine and thiamine are sufficiently 
acidic to cause the nitro to nitrosyl conversion. The pl(, of most nitro to nitrosyl 
conversions is about 6, and is kinetically slow (tY, z 8 hr). The reaction mixture has 
reached a lower pH for the conversion to proceed at room temperature in a matter of 
hours.7'11 
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Figure I a 
Cyclic Voltammetry of [Ru(bpy)1(N02)Guanine](PF6)1 
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Figure I b 
Cyclic Voltammetry of [Ru(bpy),(N01)Cytosine](PF 6), 
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Figure I c 
Cyclic Voltammetry of [Ru(bpy)2(N02)Adenine)(PF6)2 
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Figure I d 
Cyclic Voltammetry of [Ru(bpy)2(N02)ThiamineJ(PF6)2 
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Figure la-d: Cyclic Voltammetry scans of Ruthenium Nitro complexes, in 0.1 OM 
TBAH, using platinum working electrode, Silver reference electrode, IOOmv/s scan 
rate. 
Infrared spectroscopy - Infrared spectroscopy using acetonitrile as a solvent 
was used to ascertain the presence or absence of the nitrosyl group. The spectra 
obtained are shown in Figures 2 and 3. The three major acetonitrile peaks are 
generally found between 3100-2800 cm", 1600-1400 cm", 1100-1000 cm·1.12 The 
[Ru(bpy)2(N02)(N0)]3+ complex shows anitrosyl band at 1943 cm·1.12 
Interestingly, the [Ru(bpy)2(N02)(Guanine)] + complex is the only one that shows a 
clear absence of the nitrosyl ligand. All other complexes, particularly the thiamine 
and adenine derivatives, show some evidence of nitrosyl. This is particularly 
remarkable as the azido displacement reaction is quantitative.11 
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Figure 2 
Infrared Spectra of varying Ruthenium Nitro Compounds 
.... 
30 
•• 
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"'' 
Figure 2: Compiled Infrared spectra of Ruthenium Nitro complexes of interest 
dissolved in acetonitrile and run in a NaCl liquid cell. (Dark Blue- 
[Ru(bpy )i(N02X Guanine) ](PF 6)2, Maroon-[Ru(bpy )i(N02)( Adenine )](PF 6)2, 
Green-[Ru(bpy)2(N02)(Cytosine)](PF6)2, Light Blue- [Ru(bpy)i(N02)(NO)](PF,)2, 
Red- [Ru(bpy),(N02)(Thiamine)](PF6)2). 
Figure 3a 
m Spectra of [Ru(bpy)2(N02)(NO)](PF J2 
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Figure 3b 
IR Spectra of [Ru(bpy)l(N02)Guanine)(PF •)2 
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Figure 3c 
m Spectra of [Ru(bpy)2(N02)Cytosine](PF.)2 
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Figure 3d 
IR Spectra of [Ru(bpy)2(N02)Adenine](PF6)2 
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Figure 3e 
IR Spectra of [Ru(bpy)z(N02)Tbiamine](PF6)2 
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Figure 3a-e: Infrared Spectra of [Ru(bpy)z(N02)(L)](PF6)z where L= nitrosyl, 
guanine, cytosine, adenine, or thiamine, run in a NaCl liquid cell. 
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NMR spectroscopy - 
1H-NMR scans were taken of all complexes studied, and 13C 
NMR scans were taken of ruthenium nitro nitrosyl and a sample of 2,2 '-bipyridine 
(Figures 4-9). Figure 4 shows the 1H spectra of2,2'-bipyridine with the expected four 
groups located from 9- 7 .2 ppm region indicated by four peaks pertaining to four unique 
protons (hydrogen) on each cyclic structure. There were two doublet peaks and two 
triplet peaks, which pertain to the four hydrogens on the 2,2'-bypryidine groups. 
__ N 
Note that in the complex, the H4 and H,' hydrogens will sterically interfere in the 
complex, causing some degree of non-planarity. This will cause the proton resonances to 
split slightly. 
The 13C spectra show prominent, unique carbon resonances or possibly two 
resonances at 156 ppm. The spectra of2 in Figure 6 demonstrates the same multiplet 
peaks in the 9.5-7.5 ppm region of the 2-2' -bipyridine. However, these peaks were 
surrounded by a great deal of other multiplet peaks. 
Spectra of Figure 8-11 shows the effects of the loss of two symmetry axes upon 
coordination to the [Ru(N02)(NO)] group, and the concomitant deshielded shift due to 
the electron withdrawing of the Ru11-NO+ group. Loss of NO+ by reaction with N3- 
results in a 0.5-1 ppm shielded shift of the aromatic proton resonance. However, both the 
cytosine and thiamine ruthenium compounds had very intense peaks throughout the 2,2' - 
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bypyridine region. There were less intense peaks from 9- 7 ppm for the ruthenium­ 
guanine complex, however, as well as the ruthenium-adenine complex. A very large peak 
was found around 5-4 ppm on the guanine-ruthenium, cytosine-ruthenium, ruthenium­ 
adenine and thiamine-ruthenium complex's scans, most likely indicating the DOH from 
the deuterium oxide solvent. The ruthenium-adenine demonstrated very minor peaks at 6 
ppm, 3.2 ppm, 2.3 ppm, 2.1 ppm, 1.8 ppm and 1.9 ppm. Ruthenium-cytosine 
demonstrated intense peaks at 5.8 ppm, 3.5 ppm, 2.2 ppm, 2.1 ppm, and 1.9 ppm. The 
ruthenium thiamine compound demonstrated intense peaks at 5.3 pm, 2.4 ppm and 2.3 
ppm. This compound demonstrated smaller peaks at 3.7 ppm and 3.1 ppm as well. The 
ruthenium guanine compound scan only demonstrated minor peaks at 6 ppm and 2.3 
ppm, as well as very minor peaks at 3.5 ppm, 3.2 ppm, 1.9 ppm, 1.8 ppm. There was an 
intense peak demonstrated at 2.1 for the guanine compound as well. These various peaks 
are not found in the ruthenium nitro nitrosyl compounds scan. The various peaks in the 
ruthenium DNA compounds could possibly pertain to the free DNA nucleobase or 
thiamine in sample. 
The weak complex spectra cannot be further interpreted; other than the shifts are 
consistent with the pattern ofligand substitution of the saturated samples with a lowering 
of complex charge and bonding of the base. The three ruthenium- DNA nucleobase and 
thiamine compounds were found to have very large water peaks around 3 ppm when 
dissolved in deuteroacetone. This peak persisted after the compounds were aggressively 
dried by first dissolving the compounds in acetonitrile, and re-precipitating in dry ether. 
The compounds were then stored in a vacuum desiccator for several days before analysis. 
This demonstrates the compounds high affinity to absorb water, suggesting that this could 
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be a possible inhibitor of the sixth ligand substitution reaction with the ruthenium metal 
center. 
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Figure 4 
1H NMR of2'2-bipyridine in Deutero-Acetone 
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Figure 4: 1H NMR of 2'2-bipyridine in Deutero-Acetone 
Figure 5 
13C NMR of 2 '2-bipyridine in Deutero-Acetone 
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Figure 5: 13C NMR of2'2-bipyridine in Deutero-Acetone 
Figure 6 
1H NMR of [Ru(bpy)2(N02)(NO))(PF6)z in Deutero-Acetone 
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Figure 6: 1H NMR of [Ru(bpy),(N02)(NO)](PF6)2 in Deutero-Acetone 
Figure 7 
13C NMR of [Ru(bpy)2(N02)(NO))(PF6)z in Deutero-Acetone 
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Figure 7: 13C NMR of [Ru(bpy),(N02)(NO)](PF6), in Deutero-Acetone 
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Figure 8 
1
H NMR of Ruthenium-Nitro-Guanine in 020 
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Figure 8: 1H NMR of Ruthenium-Nitro-Guanine in D20 
Figure 9 
1
H NMR of Ruthenium-Nitro-Adenine in 020 
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Figure 9: 
1
H NMR of Ruthenium-Nitro-Adenine in 020 
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Figure 10 
1
H NMR of Ruthenium-Nitro-Cytosine in 020 
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Figure 10: 1H NMR of Ruthenium-Nitro-Cytosine in D20 
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Figure 11  
1H NMR of Ruthenium-Nitro-Thiamine in D20 
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Figure 11: 1HNMRofRuthenium-Nitro-Thiamine in D20 
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Bonding of [Ru(bpy)i(NO:i)(NO)](PF6)i with Z8A -The ZSA 8 mer (CG)4 DNA 
sequence reacted with excess ruthenium nitro compound was separated using size 
exclusion chromatography in order to determine whether some of the ruthenium 
compound bonded to the DNA strand (a CGCGCGCG sequence). The blue dextran, used 
due to its larger size as a void volume, band was distinct and was eluted first with the 
void volume. Following the blue dextran band, there were two additional bands 
observed, a yellow band and an orange band. This suggests that the yellow band was the 
DNA strand bound to the ruthenium compound, and the orange band was the excess 
ruthenium compound. By the presence of two bands, it is suggested that the ruthenium 
compound does bind to a DNA strand containing guanine and cytosine readily, even 
without adjacent guanines present. 
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Discussion Section 
Syntheses - The starting material is prepared by thermal ligand substitution of er 
byN02-: 
Ru(bpy)2Clz + excess N02----> Ru(bpy)z(N02)2 + 2 er 
Conversion of the nitro group to nitrosyl takes place via an acid-base reaction,8•10·11· 
Ru(bpy)2(N02)2 + 2 Ir ---> [Ru(bpy)2(N02)(N0)]2+ + H20 
in the solid phase, catalyzed by glass beads.13 It has been established that azide ion can 
gently remove the nitrosyl ligand at room temperature, affording a mild pathway for 
opening up a coordination site on the ruthenium metal center" 
[Ru(bpy)2(N02)(N0)]2+ + N3----> [Ru(bpy)2(N02)(S)t + N2 + N20 (S = solvent, 
typically acetonitrile, acetone or water). This has been exploited to produce a variety of 
bimetallic complexes of ruthenium. 13 
The electrochemical behavior of polypyridyl nitro and nitrosyl complexes of 
ruthenium are each quite distinctive. The oxidation of complexes of the general formula 
[RutpolypyridyljfblOjj]" to the Rum results in an N-bound to 0-bound isomerization, 
followed by disproportionation of the nitroso ligand to nitrosyl and nitrato ligands: 
[(bpy)2RunL(N02)t---> [(bpy)2RumL(N02)]2+ + e----> [(bpy)2RumL(ONO)t---> 
[(bpy)2RumL(ONO)t + [(bpy)2RuuL(N02)t---> [(bpy)2Ru11L(N0)]2+ + 
[(bpy)2Ru11L(ON02)t 
This isomerization reflects the increase in hardness of the Ru ion upon oxidation from the 
II to III oxidation state. Harder acids will form more stable complexes with harder 
donors. Nitrogen is a borderline donor, while oxygen is a hard donor. The return 
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reduction peaks are due to the 0-bound nitrito complex and the nitrato complex. This 
cyclic voltammetry pattern is diagnostic of the presence of the nitro group." 
The electron transfer processes of nitrosyl complexes generally have nitrosyl 
centered reductions," The first reduction is reversible, while the second leads to products 
highly dependent on the media.9 We did not focus on the second reduction, but noted the 
presence or absence of the characteristic reduction in the 300 m V vs SCCE region as a 
signifier of the presence of the nitrosyl ligand. This reduction is important to the long­ 
range goals of the project, in that polypyridyl ruthenium(II) nitrosyl complexes can be 
reduced by many biological species, including nicotine adenine dinucleotide (NAD).6 
The in vivo formation of the coordinated nitroxide radical is an interesting potential 
chemistry to be exploited in further studies. The key issue to be investigated in this work 
is the possibility of binding of [Ru(bpy)2(N02)(S)t to the bases found in nucleic acids. 
Electronic spectroscopy - The spectroscopic and electrochemical studies allowed 
a number of conclusions to be drawn, not the least of which that 
[Ru(bpy)2(N02)Solvent]2+ was able to bind to guanine. The starting 
[Ru(bpy)2(N02)(N0)]2+ has a weak Amax at 380 nm (e = 5 x 102 M-1). The product of the 
azide reaction is [Ru(bpy)2(N02)(Solvent)]\ which is water in the spectroscopic 
measurements. The absorption max for [Ru(bpy)i(N02)(0H2)t in water is 433 nm with 
an extinction coefficient 3765 at pH 8.36.5 Reaction with cytosine yields a product with 
the same absorption maximum as the starting material, suggesting no reaction. The 
products of the reactions of [Ru(bpy)2(N02)(Solvent)t with guanine, thiamine and 
adenine show increasingly red-shifted absorption maxima ( 418, 460 and 468 nm, 
respectively). Furthermore, the guanine complex shows a pronounced shoulder at 468. 
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The absorption at 418 nm for the guanine complex is consistent with a Rull � bpy charge 
transfer band with relatively strong field spectator ligands, such that you would expect for 
Ru(II) coordinating to an imine such as the N-7 site of guanine. The shoulder is assigned 
to a Ru(II)-+1t' (guanine) charge transfer band. Thiamine may coordinate to either an 
imine, amine site or the sulfur site. 
This immediately suggests there was bonding between the ruthenium- nitro and 
the guanine, because ruthenium(II) preferentially binds to nitrogen donors that act as 1t 
acceptors, which in this case would be the available nitrogen in guanine. This also 
suggests the reaction is particularly favorable. This is thought to be due to the 
availability of the N7 on the guanine, as well as the lack of steric hindrance. It is 
hypothesized that the other DNA bases are too crowded to allow imine bonding. This is 
consistent with the theory that this ruthenium compound would behave similarly to 
cisplatin when binding with DNA, preferring the guanine base. 
Electrochemistry - Cyclic voltammetry is a particularly powerful method for 
identifying, characterizing and verifiying the purity of polypyridyl ruthenium complexes. 
The Ru(III)/Ru(II) reduction potential is uniquely specific to a given ligand environment, 
and in the case of nitro and nitrosyl complexes, the shape of the cyclic voltammogram 
wave is highly distinctive for each of these ligands. 7JO,ZI In this technique, the voltage is 
linearly ramped in a three electrode cell, and the current measured. Analyte diffusion at 
the electrode surface limits the measured current of an unstirred solution. Semimicro 
electrodes ( ca 1 mm in diameter) are used so that the analyte solution is not significantly 
perturbed. Peaks will form as the compound is oxidized, and the current increases until 
the analyte is depleted at the electrode surface and the reduction potential is passed. 
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Identical peaks will form as the current is reversed and the compound is re-oxidized. 
Unsymmetrical peaks or an extreme difference between oxidation and reduction peaks 
indicate a non-reversible reaction, either due to slow electron exchange with the electrode 
surface (kinetic irreversibility) or chemical reaction following electron transfer. The 
latter is the case for oxidation of nitro complexes of ruthenium, because the Ru(II) is 
transformed to Ru(III), preventing a return peak from forming because of the slow rate of 
linkage isomerism alluded to above. This is evident from a nonsymmetric scan on the 
voltammetry scan. All complexes showed the characteristic chemically irreversible 
cyclic voltammogram associated with polypyridyl ruthenium nitro complexes, verifying 
the presence of the nitro group. In the case of the complexes synthesized from the 
hydrochloride salts ( adenine and thiamine), the wave for the nitrosyl is observed as well. 
The wave heights indicate roughly equal amounts of the No2• and NO+ present. Since 
the azido displacement of nitrosyl is quantitative, this suggests that the acid-base 
conversion of the coordinated nitro to nitrosyl takes place after the azide reaction. 
Resynthesis with excess azide did not change this result. This does not confirm binding 
of the organic base, but is an interesting observation nonetheless. In the future, the 
syntheses should be attempted with the free base. 
Infrared spectroscopy - The infrared spectra confirm complete loss of the nitrosyl 
following reaction with azide, except in the case of the bases used as hydrochloride salts. 
The latter observation confirms the cyclic voltammetry results. 
NMR Spectroscopy- The spectra of all the complexes demonstrated a deshielded 
shift as a result of the removal of the strong field ligand nitrosyl. This demonstrates that 
the bipyridine groups are less shielded as a result of a weaker field ligand (DNA 
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nucleobase, water, or solvent) taking up the sixth ligand position. Because only good 
spectra was obtained of the 2'2-bypridine and the ruthenium nitro nitrosyl complexes, it 
is clear that further results could not be obtained without using water suppression NMR 
methods. 
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Conclusions 
The various spectroscopic techniques examined above confirm the hypothesis that 
[Ru(bpy)2(N02)(0H2)t forms complexes with guanine, adenine and thiamine. It is 
particularly remarkable that the bases yield complexes with distinctly different electronic 
spectra, suggesting that each will bond with [Ru(bpy)2(N02)(0H2)t in a unique fashion. 
The extinction coefficients are all in the range associated with the sixth position being 
occupied by a borderline to moderately strong field ligand. This is important information 
because the sixth position on the ruthenium is the only variable in the different synthesis 
results. By nature, the ruthenium compound has two bipyridine groups and a nitro group 
that will remain attached to the metal center.6•8•11•17 Operating under this assumption, the 
nature of the extinction coefficients and the A.max shifts demonstrate that the guanine is the 
most electron density withdrawing of the four compounds produced. Guanine presents 
the best case of an aromatic nitrogen at N-7 in a sterically uncongested location. The 
highest energy absorption maximum attests to the strongest field interaction of the three 
bases showing bonding. 
Theoretical structure of Ruthenium 2,2'-bipyridine nitro nitrosyl 
Theoretical structure of Ruthenium 2,2 '-bipyridine nitro guanine 
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The structure of adenine suggests the possibility of binding to heavy metal centers 
because it closely resembles that of guanine. Like guanine, adenine is comprised of two 
attached cyclic structures with nitrogen incorporated in the ring. N7 on adenine does 
appear to be sterically available, like the N7 site in guanine, but the adenine complex has 
a I.max of 460 nm, which is considerably lower energy than the 418 nm observed for 
guanine. This suggests at the least that the bonding interaction is weaker field, and may 
be due to bonding to the primary amine site rather than N-7 or distortion from the amine 
group. 
All the lone pair bearing nitrogens in cytosine are sterically crowded. NI in 
cytosine is shielded from large molecule bonding due to the adjacent double bonded 
oxygen at the C2 site. In order for bonding to occur at the N3 site, the amine attached to 
the C4 would have to be twisted out of plane, involving more energy. 
The voltamrnograms of the thiamine and adenine reaction products present 
evidence for the presence of both the nitro and nitrosyl ligands. As stated above, the 
amount of sodium azide used was enough to cleave all nitrosyl groups present. Because 
two different sets of synthesis products were run on the voltamrnograms, and both sets of 
data demonstrated the nitrosyl groups present for the compounds that started with 
hydrochloride salts, clearly indicating that the hydrochloride salt of these ligands is acidic 
enough to partially convert some of the nitro groups to nitrosyl. Cytosine was also found 
to only have the nitrosyl peak, but this is thought to be due to conversion of the solveto­ 
nitro complex to the nitrosyl as the UV spectroscopy results suggest there was no binding 
between the cytosine and the ruthenium metal center. 
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The IR scans show a somewhat broad peak in the 3600-3500 cm" region for the 
ruthenium nitro nitrosyl compound, which seems to disappear in all the ruthenium-DNA 
nucleobase scans. In particular, the peak seems to have disappeared all together in the 
presence of the adenine and guanine. This is likely due to the multiple waters of 
hydration expected for the polycationic nitro nitrosyl complex. The metal base 
complexes are expected to have fewer waters of hydration due to the lower charge and 
the fact that the cation was deeply buried within the organic ligand framework. 
The infrared peak found at 1630 cm" for the ruthenium nitro nitrosyl compound 
is characteristic of the nitrosyl group. This peak disappears in the spectrum of the 
product of the guanine reaction consistant with loss of the NO+ group upon reaction with 
azide. There is a very minor peak found in the ruthenium-adenine complex, however, 
again suggesting there is nitrosyl present in the solution, but in a very small amount in 
comparison with the ruthenium nitro nitrosyl complex. 
NMR results did not produce clear enough spectra to conclude definite structures 
due to the insolubility of the compounds in a variety of solvents. Only very dilute 
samples were available for analysis. The 1H-NMR scans for the various compounds did, 
however, produce interesting results. The deshielded shift of the DNA nucleobase­ 
ruthenium and thiamine-ruthenium compounds confirms removal of the strong field 
ligand nitrosyl and replacement with a weaker field ligand. However, little more about 
the specific substitution molecule could be discerned as there was a great deal of water in 
the complex. Again, guanine, cytosine, adenine, and thiamine ruthenium compounds all 
had intense water peaks when dissolved in deuteroacetone, demonstrating their high 
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affinity for water. Water suppression NMR studies are suggested for these complexes to 
get more informative data on the configuration of these compounds. 
Two distinct, highly colored bands were observed when the product of the 
reaction between in situ produced [Ru(bpy)2(N02)(Solvent)t and Z8 mer DNA was 
separated on a size exclusion column. This confirms that some complex ion binding to 
the (CGCGCGCG) DNA sequence is occurring. This result supports the conclusions 
from the spectroscopic data that the ruthenium nitro compound is in fact bonding at the 
guanine site. More importantly, it demonstrates that the ruthenium compound will bind 
to a DNA sequence very easily without requiring sensitive environmental conditions. It 
is therefore likely that ruthenium nitro nitrosyl is a viable drug option as it will bind to 
guanine bases in DNA strands, and most likely disable the above mentioned strand. 
Further investigation into this drug option should include various bonding studies of the 
ruthenium nitro nitrosyl compound with other DNA strands, most notably those with a 
GG site such as COTAR2. If bonding with these strands proves to be successful, studies 
of full tissue cells introduced with the ruthenium nitro nitrosyl compound should be 
conducted in order to determine if the cell cytoplasm will harbor the nitro to nitrosyl 
conversion, which would then enable the reduction by NADH to the nitroxide species. 
As mentioned above, this nitroxide is rapidly consumed in cells and could become 
another exciting avenue of anti-tumor properties of this particular ruthenium compound. 
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